Literature DB >> 22656400

Dextromethorphan in the treatment of early myoclonic encephalopathy evolving into migrating partial seizures in infancy.

Yin-Hsuan Chien1, Ming-I Lin, Wen-Chin Weng, Jung-Chieh Du, Wang-Tso Lee.   

Abstract

Epileptic encephalopathy with suppression-burst in electroencephalography (EEG) can evolve into a few types of epileptic syndromes. We present here an unusual case of early myoclonic encephalopathy that evolved into migrating partial seizures in infancy. A female neonate initially had erratic myoclonus movements, hiccups, and a suppression-burst pattern in EEG that was compatible with early myoclonic encephalopathy. The seizures were controlled with dextromethorphan (20 mg/kg), and a suppression-burst pattern in EEG was reverted to relatively normal background activity. However, at 72 days of age, alternating focal tonic seizures, compatible with migrating partial seizures in infancy, were demonstrated by the 24-hour EEG recording. The seizures responded poorly to dextromethorphan. To our knowledge, this is the first reported case of early myoclonic encephalopathy evolving into migrating partial seizure in infancy. Whether it represents another age-dependent epilepsy evolution needs more clinical observation.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22656400     DOI: 10.1016/j.jfma.2012.03.007

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  1 in total

1.  Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum.

Authors:  Amy McTague; Richard Appleton; Shivaram Avula; J Helen Cross; Mary D King; Thomas S Jacques; Sanjay Bhate; Anthony Cronin; Andrew Curran; Archana Desurkar; Michael A Farrell; Elaine Hughes; Rosalind Jefferson; Karine Lascelles; John Livingston; Esther Meyer; Ailsa McLellan; Annapurna Poduri; Ingrid E Scheffer; Stefan Spinty; Manju A Kurian; Rachel Kneen
Journal:  Brain       Date:  2013-04-18       Impact factor: 13.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.